Vor Ort
Merkzettel Warenkorb
Produktbild: Tumors of the Central Nervous System, Volume 2
Band 2

Tumors of the Central Nervous System, Volume 2 Gliomas: Glioblastoma (Part 2)

Aus der Reihe Tumors of the Central Nervous System

187,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

29.05.2013

Abbildungen

XXII, 458 p.

Herausgeber

Hayat

Verlag

Springer Netherland

Seitenzahl

458

Maße (L/B/H)

26/19,3/2,6 cm

Gewicht

993 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-94-007-3580-4

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

29.05.2013

Abbildungen

XXII, 458 p.

Herausgeber

Hayat

Verlag

Springer Netherland

Seitenzahl

458

Maße (L/B/H)

26/19,3/2,6 cm

Gewicht

993 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-94-007-3580-4

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Tumors of the Central Nervous System, Volume 2

  • Chapter 1.
    INTRODUCTION. I.
    BIOMARKERS AND DIAGNOSIS. Chapter  2.
    GLIOMAGENESIS: ADVANTAGES AND LIMITATIONS OF BIOMARKERS.
    Chapter  3.
    MOLECULAR SUBTYPES OF GLIOMAS.
    Chapter  4.
    GLIOBLASTOMA: GERMLINE MUTATION OF
    TP53.
    Chapter  5.
    GLIOMAS: ROLE OF THE
    TP53
    GENE.
    Chapter  6.
    THE ROLE OF IDH1 AND IDH2 MUTATIONS IN MALIGNANT GLIOMAS.
    Chapter  7.
    MALIGNANT GLIOMA: ISOCITRATE DEHYDROGENASES 1 AND 2  MUTATIONS.
    Chapter  8.
    METABOLIC DIFFERNCES IN DIFFERENT REGIONS OF GLIOMA SAMPLES.
    Chapter  9.
    GLIOBLASTOMA PATIENTS: ROLE OF METHYLATED MGMT.
    Chapter  10
    . BRAIN TUMOR ANGIOGENESIS AND GLIOMA GRADING: ROLE OF TUMOR BLOOD VOLUME AND PERMEABILITY ESTIMATES USING PERFUSION CT.
    Chapter 11.
     VASCULOGENIC MIMICRY IN GLIOMA.
    Chapter 12.
    NEWLY DIAGNOSED GLIOMA: DIAGNOSIS USING POSITRON EMISSION TOMOGRAPHY WITH METHIONINE AND FLUOROTHYMIDINE.
    Chapter  13.
    ROLE OF DIFFUSION TENSOR IMAGING IN DIFFERENTIATION OF GLIOBLASTOMAS FROM  SOLITARY BRAIN METASTASES.
    Chapter  14.
    I-TM-601 SPECT IMAGING OF HUMAN GLIOMA.
    Chapter  15.
    ASSESSMENT OF BIOLOGICAL TARGET VOLUME USING POSITRON EMISSION TOMOGRAPHY IN HIGH-GRADE GLIOMA PATIENTS.
    Chapter  16.
    SKIN METASTASES OF GLIOBLASTOMA. II.
    THERAPY. Chapter 17.
    DIFFUSE LOW-GRADE GLIOMAS. WHAT DOES “COMPLETE RESECTION” MEAN?
    Chapter 18.
    QUANTITATIVE APPROACH OF THE NATURAL COURSE OF DIFFUSE LOW-GRADE GLIOMAS.
    Chapter  19.
    IMPACT OF RESECTION EXTENT ON OUTCOMES IN PATIENTS WITH HIGH-GRADE GLIOMAS.
    Chapter 20.
    RECURRENT MALIGNANT GLIOMAS: 5-AMINOLEVULINIC ACID FLUORESCENCE-GUIDED RESECTION.
    Chapter 21.
    GLIOMA SURGERY: INTRAOPERATIVE LOW FIELD MAGNETIC RESONANCE IMAGING.
    Chapter  22.
    LOW-GRADE GLIOMAS: INTRAOPERATIVE ELECTRICAL STIMULATIONS.
    Chapter  23.
    MALIGNANT GLIOMAS: PRESENT AND FUTURE THERAPEUTIC DRUGS.
    Chapter 24.
    RECURRENT MALIGNANTGLIOMA PATIENTS: TREATMENT WITH CONFORMAL RADIOTHERAPY AND SYSTEMIC THERAPY.
    Chapter  25.
    GLIOBLASTOMA: BORON NEUTRON CAPTURE THERAPY.
    Chapter  26.
    GLIOBLASTOMA: ANTI-TUMOR ACTION OF CYCLOSPORINE A AND FUCTIONALLY RELATED DRUGS.Chapter 27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE.
    Chapter  28.
    GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE.
    Chapter  29.
    GLIOMA-INITIATING CELLS: INTERFERON TREATMENT.
    Chapter  30.
    GLIOBLASTOMA : ANTITUMOR ACTION OF NATURAL AND SYNTHETIC  CANNABINOIDS.
    Chapter  31.
    PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN.
    Chapter 32.
    MONITORING GLIOMAS
    IN VIVO
    USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY –INDUCED APOPTOSIS.
    Chapter 33.
    HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY.
    Chapter 34.
    GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS.
    Chapter 35.
    FISCHER-F98 GLIOMA MODEL: METHODOLOGY.
    Chapter  36.
    CELLULAR CHARACTERIZATION OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL  GLIOMA.
    Chapter  37.
    ADULT BRAINSTEM GLIOMAS: DIAGNOSIS AND TREATMENT .
    Chapter  38
    . USE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS. III.
    PROGNOSIS. Chapter 39.
    BRAINSTEM GLIOMAS: AN OVERVIEW.
    Chapter  40.
    TUMOR-ASSOCIATED EPILEPSY IN PATIENTS WITH GLIOMA.
    Chapter 41.
    CHRONIC EPILEPSY ASSOCIATED WITH BRAIN TUMORS: SURGICAL NEUROPATHOLOGY.
    Chapter 42.
    LOW-GRADE GLIOMAS: ROLE OF RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION.
    Chapter 43.
    ANGIOCENTRIC GLIOMA- INDUCED SEIZURES: LESIONECTOMY.